Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study.

TitleLactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study.
Publication TypeJournal Article
Year of Publication2014
AuthorsFrancavilla, R, Polimeno, L, Demichina, A, Maurogiovanni, G, Principi, B, Scaccianoce, G, Ierardi, E, Russo, F, Riezzo, G, Di Leo, A, Cavallo, L, Francavilla, A, Versalovic, J
JournalJ Clin Gastroenterol
Volume48
Issue5
Pagination407-13
Date Published2014 May-Jun
ISSN1539-2031
KeywordsAdolescent, Adult, Aged, Anti-Bacterial Agents, Breath Tests, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Gastrins, Helicobacter Infections, Helicobacter pylori, Humans, Lactobacillus reuteri, Male, Middle Aged, Probiotics, Prospective Studies, Treatment Outcome, Young Adult
Abstract

GOALS: The goals of this study were to investigate the role of a new probiotic preparation (Lactobacillus reuteri DSM 17938 and L. reuteri ATCC PTA 6475) in Helicobacter pylori infection.

BACKGROUND: Specific probiotic strains play a role in H. pylori infection for their ability to decrease bacterial load and gastritis, prevent antibiotic-associated side effects, and increase the eradication rate.

STUDY: This is a prospective, double-blind, randomized, placebo-controlled study in a tertiary care setting. A total of 100 H. pylori-positive naive patients received either L. reuteri combination (2×10 Colony Forming Units) or placebo during a 3-phase study (pre-eradication, eradication, and follow-up). All underwent C urea breath test (C-UBT), blood assessments of gastrin-17 (G17), endoscopy, and the Gastrointestinal Symptom Rating Scale. Eradication was confirmed by C-UBT 8 weeks after the completion of therapy.

RESULTS: Fifty patients were allocated in each group. During pre-eradication period, C-UBT δ decreased by 13% in L. reuteri combination as compared with a 4% increase in placebo (-13.2±34% vs. 4.3±27%; P

CONCLUSIONS: L. reuteri combination alone is able to exert an inhibitory effect on H. pylori growth, and when administered with eradication therapy, it determines a significant reduction in antibiotic-associated side effects. Moreover, L. reuteri combination was able to decrease serum G17 levels and to (not significantly) increase the H. pylori-eradication rate.

DOI10.1097/MCG.0000000000000007
Alternate JournalJ. Clin. Gastroenterol.
PubMed ID24296423